Please assess the completion status of the following clinical trial:

Trial Title: Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed aggressive B-cell non-Hodgkin's lymphoma, including the following subtypes:~  * Grade 3 follicular lymphoma~ * Diffuse B-cell lymphoma, including diffuse large cell lymphoma with any of the following variants:~    * Centroblastic~   * Immunoblastic~   * Plasmablastic~   * Anaplastic large cell~   * T-cell-rich B-cell lymphoma~ * Primary effusion lymphoma~ * Intravascular B-cell lymphoma~ * Primary mediastinal B-cell lymphoma~ * Burkitt's or Burkitt-like lymphoma~ * Mantle cell lymphoma (blastoid)~ * Aggressive marginal zone lymphoma (monocytoid)~* Previously untreated disease~* CD20-positive disease~* International Prognostic Index (IPI) score 0~* No bulky disease~  * Largest single or conglomerate tumor \< 7.5 cm in diameter~* No mucosa-associated lymphoid tissue (MALT) lymphoma~* No CNS involvement of lymphoma (intracerebral, meningeal, or intraspinal)~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Platelet count ≥ 100,000/mm\^3~* WBC ≥ 2,500/mm\^3~* Lactate dehydrogenase normal~* Not pregnant or lactating~* Fertile patients must use effective contraception during and for 1 year after study participation~* Negative pregnancy test~* No known hypersensitivity to the study medications~* No known HIV-positivity~* No active hepatitis infection~* No impaired left ventricular function~* No severe cardiac arrhythmias~* No other impaired organ function~* No other serious disorder~* No other malignancy within the past 5 years except carcinoma in situ or basal cell skin cancer~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy~* No prior immunosuppressive treatment with cytostatics~* No planned radiotherapy to extranodal involvement~* No concurrent participation in other treatment studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Interventional: 6 R-CHOP-21 (Type: ACTIVE_COMPARATOR): Arm I: Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 3 more courses of R-CHOP.
- Interventional: 4 R-CHOP-21 + 2 x R (Type: ACTIVE_COMPARATOR): Arm II: Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 1 more course of R-CHOP followed by 2 courses of rituximab alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).